| 17.59 0 (0%) | 09-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S is a biotechnology firm focused on the discovery, development, and commercialization of peptide-based medications. The company's therapeutic pipeline and marketed products primarily address gastrointestinal and metabolic diseases, as well as other niche conditions with significant unmet medical needs. Currently, Zealand Pharma markets lixisenatide under the brand names Adlyxin and Lyxumia. Its product portfolio also includes Dasiglucagon, offered as a single-use syringe or autoinjector for managing severe hypoglycemia, congenital hyperinsulinism, and post-bariatric surgery hypoglycemia, alongside its use in a dual-hormone artificial pancreas for automated diabetes care. In its advanced development stage, Dasiglucagon is progressing through Phase III clinical trials for congenital hyperinsulinism. Another significant late-stage asset is glepaglutide, a long-acting GLP-2 analogue, also in Phase III trials for the treatment of short bowel syndrome. Zealand Pharma A/S has established key collaboration agreements with entities such as Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Fri, 12 Jun 2026
Zealand Pharma A/S (ZEAL.CO) Stock Price, News & Analyst Forecast - eToro
Wed, 10 Jun 2026
Transactions in Zealand Pharma shares and/or related - GlobeNewswire
Tue, 09 Jun 2026
ZEAL: Obesity drug focus shifts to metabolic health, with flexible dosing and strong pipeline momentum - TradingView
Tue, 09 Jun 2026
Transcript : Zealand Pharma A/S Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01 - marketscreener.com
Mon, 08 Jun 2026
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026) - GlobeNewswire
Mon, 08 Jun 2026
Zealand Pharma increases its share capital as a result of the exercise of employee warrants - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|